Acute Lymphoid Leukemia Clinical Trial
Official title:
Phase 2 Study of the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity (A3B1) Conjugated With the Co-stimulatory Regions 4-1BB and CD3z (ARI-0001 Cells) in Patients With CD19+ Acute Lymphoid Leukemia Resistant or Refractory to Therapy
To assess the efficacy (in terms of response rate and duration) of the infusion of ARI-0001 cells (Adult differentiated autologous T-cells from peripheral blood, expanded and transducted with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity [A3B1] conjugated to the 4-aBB and CD3z co-stimulatory regions) in patients with resistant or refractory CD19+ acute lymphoid leukemia
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05959720 -
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
|
||
| Recruiting |
NCT02933333 -
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
|
Phase 4 | |
| Completed |
NCT02953730 -
The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents
|
Phase 4 | |
| Completed |
NCT02767388 -
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
|
||
| Recruiting |
NCT03610438 -
Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia
|
Phase 2 | |
| Recruiting |
NCT05792007 -
Study of the Medullary Microenvironment in Acute Childhood Leukemia
|
N/A | |
| Completed |
NCT02294552 -
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
|
Phase 2 | |
| Completed |
NCT01461538 -
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
|
Phase 2 | |
| Recruiting |
NCT04167683 -
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
|
||
| Recruiting |
NCT05150561 -
Muscle Dysfunction in Patients With Haematological Diseases
|
||
| Active, not recruiting |
NCT04669210 -
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
|
Phase 2 | |
| Recruiting |
NCT04013685 -
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT02345915 -
Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia
|
N/A | |
| Completed |
NCT01720264 -
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
|
Phase 2 | |
| Not yet recruiting |
NCT02413021 -
The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens
|
Phase 1 | |
| Recruiting |
NCT03448393 -
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
|
Phase 1 | |
| Completed |
NCT03833180 -
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
|
Phase 1 | |
| Active, not recruiting |
NCT03367299 -
Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia
|
Phase 2 | |
| Terminated |
NCT02435550 -
iCare for Cancer Patients
|
N/A | |
| Recruiting |
NCT05316701 -
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
|
Phase 3 |